Drug Overview
Farxiga (dapagliflozin; AstraZeneca/Ono Pharmaceutical) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class.
It is approved for the treatment of type 2 diabetes and currently in Phase III trials for the treatment of type 1 diabetes, as well as for chronic kidney disease including diabetic nephropathy.
SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism.
They prevent filtered glucose from being reabsorbed in the kidney rather than actively facilitating glucose filtration and excretion. Due to this distinct mechanism of action, when SGLT-2 inhibitors are used as monotherapy, they do not lower glucose to unsafe levels and thus avoid the risk of hypoglycemia.
Farxiga (dapagliflozin; AstraZeneca/Ono Pharmaceutical) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class.
It is approved for the treatment of type 2 diabetes and currently in Phase III trials for the treatment of type 1 diabetes, as well as for chronic kidney disease including diabetic nephropathy.
SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism.
They prevent filtered glucose from being reabsorbed in the kidney rather than actively facilitating glucose filtration and excretion. Due to this distinct mechanism of action, when SGLT-2 inhibitors are used as monotherapy, they do not lower glucose to unsafe levels and thus avoid the risk of hypoglycemia.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
Companies Mentioned
- AstraZeneca
- Ono Pharmaceutical